[Chronic thromboembolic pulmonary hypertension: current diagnostic and treatment options: A review]

I E Chazova1

  • 1Chazov National Medical Research Center of Cardiology.

Terapevticheskii Arkhiv
|December 30, 2023
PubMed

Insights

This review covers diagnosing and treating chronic thromboembolic pulmonary hypertension (CTEPH). It details diagnostic steps, risk factors, and therapeutic options like surgery and medication for this condition.

Area of Science:

  • Cardiology
  • Pulmonology
  • Vascular Medicine

Background:

  • Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition often resulting from unresolved pulmonary emboli.
  • Understanding CTEPH's definition and risk factors is crucial for timely diagnosis and intervention.
  • Current diagnostic and therapeutic strategies are evolving to improve patient outcomes.

Approach:

  • This review outlines a four-stage diagnostic algorithm for CTEPH, detailing specific examination methods at each phase.
  • It critically evaluates therapeutic interventions, including pulmonary endarterectomy and balloon angioplasty.
  • The article also discusses the role of specific pulmonary hypertension medications in CTEPH management.

Key Points:

  • Accurate diagnosis of CTEPH involves a systematic, multi-stage approach.
  • Pulmonary endarterectomy offers a potential cure, while balloon angioplasty provides an alternative for non-operable cases.
  • Medical therapy is essential for managing pulmonary hypertension in CTEPH patients.

Conclusions:

  • Optimizing CTEPH diagnosis and treatment requires a comprehensive understanding of current guidelines and available interventions.
  • The Russian Pulmonary Hypertension Registry data offers valuable insights into clinical presentation and treatment patterns.
  • Further research and registry data are vital for refining CTEPH management strategies.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
168
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
184
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166